Trial* | Drug | All Hispanic (%) | Argentina | Brazil | Chile | Columbia | Ecuador | Guatemala | Mexico | Peru | Puerto Rico |
HARMONY | Albiglutide | 21.0 | X | X | X | ||||||
EXAMINE | Alogliptin | Not reported | X | X | X | X | X | X | X | X | |
CANVAS | Canagliflozin | Not reported | X | X | X | ||||||
EMPA-REG | Empagliflozin | 18.0 | X | X | X | X | X | ||||
EXSCEL | Exenatide | 20.5 | X | X | X | X | X | ||||
LEADER | Liraglutide | 12.1 | X | X | |||||||
ELIXA | Lixisenatide | 29.1 | X | X | X | X | X | X | |||
SAVOR-TIMI | Saxagliptin | 21.5 | X | X | X | X | X | ||||
SUSTAIN-6 | Semaglutide | 15.5 | X | X | X | ||||||
TECOS | Sitagliptin | 12.2 | X | X | X | X |
*Clinicaltrials.gov numbers: EXAMINE—NCT00968708; CANVAS—NCT01032629; EMPA-REG—NCT01131676; EXSCEL—NCT01144338; LEADER—NCT01179048; ELIXA—NCT01147250; SAVOR-TIMI—NCT01107886; SUSTAIN-6—NCT01720446; TECOS—NCT00790205; HARMONY—NCT02465515.